Ultragenyx Q2 revenue rises 13%

Overview

• Ultragenyx Q2 2025 revenue rises 13% yr/yr to $166 mln

• Company reaffirms 2025 revenue guidance of $640 mln to $670 mln

• Net loss for Q2 2025 was $115 mln

Outlook

• Ultragenyx reaffirms 2025 revenue guidance of $640 mln to $670 mln

• Company expects Crysvita revenue of $460 mln to $480 mln in 2025

• Ultragenyx anticipates Dojolvi revenue of $90 mln to $100 mln in 2025

• Company sees modest increase in net cash used due to timing delays

Result Drivers

• CRYSVITA SALES - Crysvita revenue reached $120 mln, driven by Latin America and Türkiye product sales

• DOJOLVI PERFORMANCE - Dojolvi contributed $23 mln to Q2 revenue

• EVKEEZA LAUNCH - Evkeeza revenue increased to $15 mln as launch continues outside the U.S.

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $81.00, about 64.9% above its August 4 closing price of $28.46

Press Release: ID:nGNX3XgNHH